The neutralizing antibodies to live SARS-CoV-2 were quantified using a plaque reduction neutralization test (PRNT); serum samples were first heat-inactivated for 30 min at 56°C and then diluted 1:2 in 96-well plates. After the samples were incubated for 1 h at 37°C together with 50% tissue culture infectious dose (TCID50) SARS-CoV-2, the serum/virus mixtures were added to VeroE6 cells in another 96-well plate and incubated for 1 h at 37°C. The cytopathic effect (CPE) on VeroE6 cells was analyzed at 3 days post-infection. Neutralization was defined as the absence of 50% CPE compared with virus controls, and the results were calculated by using the Reed-Muench (16) or Spearman-Kärber method (17). The positive cutoff for defining seropositivity for neutralizing antibodies to live SARS-CoV-2 was 1/4, and the neutralizing antibody detection data that were below the cutoff value were included in the analysis as half of the cutoff value.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.